Sitting in his favorite tiny red wooden chair, Teddy Christiansen peers out the window, smiling as he watches his older sister, Raelyn, play in the front yard. Before long, Teddy springs from the chair, itching to go outside himself. The bespectacled 33-month-old is everything he should be at his age:...
Latest News
CARLSBAD, Calif. — Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced favorable data from a Phase 1 single- and multiple-ascending dose (SAD/MAD) trial of DT-168 in healthy volunteers, which will be presented on May 2, 2025 at Eyecelerator @ Park...
TOKYO, Japan & BASKING RIDGE, N.J. — The first patient has been dosed in the randomization phase of the DESTINY-Ovarian01 phase 3 trial evaluating ENHERTU® (trastuzumab deruxtecan) in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy in patients with HER2 expressing (IHC 3+/2+/1+) advanced high-grade epithelial ovarian cancer...
Gainesville, Florida – Scientists have developed a saliva test that screens for breast cancer, which is showing promising results in experimental testing, according to a study published Tuesday. The new hand-held device detects breast cancer biomarkers from a tiny sample of spit, say researchers from the University of Florida and...
New York, NY – The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “Developing Biological Markers to Improve Clinical Care in Autism” on Tuesday, February 13, 2024, at 2:00 pm ET. The presenter will be James McPartland, Ph.D., Harris Professor of Child Psychiatry and Psychology at Yale School...
Matsuyama, Japan – Multiple myeloma still appears to be an incurable hematological malignancy. One of the reasons is that myeloma cells can be heterogenous and acquire resistance after anti-myeloma treatment. Immunotherapy is an attractive strategy to target myeloma cells with drug resistance. The next-generation modality which can safely and effectively...
QUEBEC, Canada — Devonian Health Group Inc. (“Devonian” or the Company) (TSXV: GSD; OTCQB: DVHGF) today announced positive results from a follow-up preclinical study evaluating Thykamine™ in a human metabolic dysfunction-associated steatohepatitis (MASH) model using PhysioMimix® Liver-on-a-Chip platform. The study was conducted by CN Bio Innovations, Cambridge, UK. Importantly, the study demonstrates that Thykamine™...
QUÉBEC, Quebec — Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to fibroinflammatory diseases, today announced additional preclinical results from its previously reported STAM™ mouse model in vivo study of metabolic dysfunction–associated steatohepatitis (MASH). These new data provide gene expression...
BOSTON, Mass. — Dewpoint Therapeutics, Inc., a clinical-stage biotechnology company pioneering condensate-modulating therapeutics, today announced the selection of a Development Candidate (DC) for its TDP-43 program. The DC is a first-in-class small molecule designed to correct disease-associated TDP-43 condensates, restoring normal TDP-43 function and addressing the core molecular pathology that...
BOSTON, Mass. — Dewpoint Therapeutics Inc., a biotechnology company that translates the novel science of condensates into breakthrough therapeutics, today announced the filing of multiple patent applications covering novel compounds and their use in the potential treatment of amyotrophic lateral sclerosis (ALS). Composition of matter covered by these applications aims...